Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2177706 | 0.78 | — | — | |
| SCHEMBL2179886 | 0.78 | ENPP2 (0.31) | PTGS2 | |
| SCHEMBL20554265 | 0.76 | — | — | |
| SCHEMBL2179257 | 0.76 | PTGS2 (0.30) | PTGS2 | |
| SCHEMBL2176790 | 0.73 | FABP3 (0.32) | — | |
| SCHEMBL2180551 | 0.73 | — | — | |
| SCHEMBL2180703 | 0.73 | PTGS2 (0.32) | PTGS2 | |
| SCHEMBL2178591 | 0.73 | SMN1; SMN2 (0.36) | PTGS2 | |
| SCHEMBL2176052 | 0.72 | SLC22A12 (0.33) | PTGS2 | |
| SCHEMBL2177005 | 0.72 | POLB (0.38) | PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4023640-A1 | PHENYLIMIDAZOLE COMPOUND | Otsuka Pharmaceutical Factory, Inc. (JP) | 2022-07-06 | — | — | EP | disclosed |
| CN-113200962-A | Phenylimidazole compounds | 株式会社大塚制药工场 | 2021-08-03 | — | — | CN | disclosed |
| CN-108430977-B | Phenylimidazole compounds | 株式会社大塚制药工场 | 2021-06-08 | — | — | CN | disclosed |
| US-10570117-B2 | Phenylimidazole compound | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2020-02-25 | — | — | US | disclosed |
| US-20180354930-A1 | PHENYLIMIDAZOLE COMPOUND | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2018-12-13 | — | — | US | disclosed |
| EP-3401310-A1 | PHENYLIMIDAZOLE COMPOUND | Otsuka Pharmaceutical Factory, Inc. (JP) | 2018-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10570117-B2 | Phenylimidazole compound | LPL, PNLIP, LIPC | PTGS2 1956/4885 |
| US-20180354930-A1 | PHENYLIMIDAZOLE COMPOUND | PNLIP, PLIN1, HDAC11 | PTGS2 2676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.